Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting

Sean A. Woolen 1 · Jonathan P. Troost 2 · Shokoufeh Khalatbari 2 · Akshat C. Pujara 3 · Jennifer S. McDonald 4 · Robert J. McDonald 4 · Prasad Shankar 5,6 · Alana A. Lewin 7 · Amy N. Melsaether 8 · Steven M. Westphal 9 · Katherine H. Patterson 9 · Ashley Nettles 5 · John P. Welby 4 · Parth Pradip Patel 4 · Neud Kiros 9 · Lisa Piccoli 7 · Matthew S. Davenport 5,6

Received: 10 December 2020 / Revised: 19 February 2021 / Accepted: 1 April 2021 / Published online: 28 May 2021 © The Author(s) 2021

Abstract

Objective It is unknown how patients prioritize gadolinium-based contrast media (GBCM) benefits (detection sensitivity) and risks (reactions, gadolinium retention, cost). The purpose of this study is to measure preferences for properties of GBCM in women at intermediate or high risk of breast cancer undergoing annual screening MRI.

Methods An institutional reviewed board-approved prospective discrete choice conjoint survey was administered to patients at intermediate or high risk for breast cancer undergoing screening MRI at 4 institutions (July 2018–March 2020). Participants were given 15 tasks and asked to choose which of two hypothetical GBCM they would prefer. GBCM attributes included the following: sensitivity for cancer detection (80–95%), intracranial gadolinium retention (1–100 molecules per 100 million administered), severe allergic-like reaction rate (1–19 per 100,000 administrations), mild allergic-like reaction rate (10–1000 per 100,000 administrations), out-of-pocket cost ($25–$100). Attribute levels were based on published values of existing GBCM. Hierarchical Bayesian analysis was used to derive attribute “importance.” Preference shares were determined by simulation.

Results Response (87% [247/284]) and completion (96% [236/247]) rates were excellent. Sensitivity (importance = 44.3%, 95% confidence interval = 42.0–46.7%) was valued more than GBCM-related risks (mild allergic-like reaction risk (19.5%, 17.9–21.1%), severe allergic-like reaction risk (17.0%, 15.8–18.1%), intracranial gadolinium retention (11.6%, 10.5–12.7%), out-of-pocket expense (7.5%, 6.8–8.3%)). Lower income participants placed more importance on cost and less on sensitivity (p < 0.01). A simulator is provided that models GBCM preference shares by GBCM attributes and competition.

Conclusions Patients at intermediate or high risk for breast cancer undergoing MRI screening prioritize cancer detection over GBCM-related risks, and prioritize reaction risks over gadolinium retention.

Key Points

• Among women undergoing annual breast MRI screening, cancer detection sensitivity (attribute “importance,” 44.3%) was
valued more than GBCM-related risks (mild allergic reaction risk 19.5%, severe allergic reaction risk 17.0%, intracranial gadolinium retention 11.6%, out-of-pocket expense 7.5%).

- Prospective four-center patient preference data have been incorporated into a GBCM choice simulator that allows users to input GBCM properties and calculate patient preference shares for competitor GBCMs.
- Lower-income women placed more importance on out-of-pocket cost and less importance on cancer detection ($p < 0.01$) when prioritizing GBCM properties.

Keywords  Magnetic resonance imaging · Mass screening · Gadolinium · Contrast media · Patient-centered care

Abbreviations
GBCM  Gadolinium-based contrast media
STROBE  Standardizing Reporting of Observational Studies in Epidemiology

Introduction

Selection of an optimal GBCM has gained focus in recent years based on evidence that a tiny quantity of gadolinium administered with GBCM is retained in the brain and body for months or years [1–4]. The clinical importance of such gadolinium retention is unknown, but is a relevant consideration, especially in young patients and those receiving repeated lifetime administrations (e.g., women at intermediate or high risk for breast cancer undergoing MRI screening) [5–7]. However, choice of gadolinium-based contrast media (GBCM) is more complex than gadolinium retention alone and influenced by its potential benefits (e.g., detection sensitivity) as well as its risks (e.g., adverse reaction rate, intracranial gadolinium retention, cost) [8].

It is currently unclear how patients prioritize this recently emphasized [6] gadolinium retention relative to other GBCM risks and benefits [8]. For example, is a GBCM with low risk of long-term gadolinium retention but low detection sensitivity and high allergic-like reaction rate preferred over a GBCM with higher risk of long-term gadolinium retention, higher detection sensitivity, and lower allergic-like reaction rate? The complex interplay between these factors can leave GBCM selection to provider gestalt, and often without patient input. The aim of this study was to measure preferences for properties of GBCM in an annual screening MRI population at greatest potential risk of GBCM-related side effects. We prospectively studied patients at risk for gadolinium retention at four centers to elicit their implied preferences for GBCM properties.

Material and methods

This Health Insurance Portability and Accountability Act-compliant prospective discrete choice conjoint survey was approved by the Institutional Review Boards at each of 4 participating institutions. Informed consent was obtained from all participants. The Standardizing Reporting of Observational Studies in Epidemiology (STROBE) guidelines were used in the preparation of this manuscript.

Study population

We conducted a prospective observational discrete choice conjoint survey at 4 institutions in Michigan, Minnesota, New York, and Indiana from July 2018 to March 2020. The institutions were chosen to support a broad range of demographic characteristics. Patients participating in breast MRI screening programs are known to have a skewed demographic distribution compared to the general population [9–13]. The inclusion criteria were chosen to reflect individuals with a vested personal interest in cancer detection and a high likelihood of repeated lifetime administrations of GBCM. Inclusion criteria were as follows: (1) outpatient, (2) intermediate or high risk for breast cancer [14] undergoing annual screening breast MRI. Exclusion criterion was previous participation in the study (N = 0). Indications for MRI were based on the American Cancer Society’s 2007 guidelines for breast cancer screening with MRI [14].

Conjoint survey development and administration

Our study design used a paired discrete choice-based conjoint survey. This type of survey provides respondents with 2 options and asks them to select which one they would prefer. Each option has a series of attributes that the investigators wish to study. In our context, those attributes were the risks and benefits of GBCM. That process is repeated multiple times. At the conclusion of the survey, implied preferences can be derived that indicate what attributes were prioritized by the respondents when making their choices.

Our discrete choice-based conjoint survey (Supplemental Material; Sawtooth Software, Inc (Provo, UT, USA); [15]) used a partial profile design and provided respondents with 15 paired choice sets. Each choice was between two unique hypothetical GBCM with the same 5 attributes set at the same or different levels (sensitivity for cancer detection [range 80–95%], intracranial gadolinium retention [range 1–100...
molecules retained per 100 million molecules administered], severe allergic-like reaction rate [range 1–19 per 100,000 administrations], mild allergic-like reaction rate [range 10–1000 per 100,000 administrations], and out-of-pocket cost [range $25–$100]). Only one answer was allowed per question. The range of most GBCM attribute levels was derived from the literature (cancer detection sensitivity [16, 17], gadolinium retention [18], severe allergic-like reaction rate [19], and mild allergic-like reaction rate) [19]. Out-of-pocket cost was informed by common co-pay rates, and online drug prices and proprietary vendor-negotiated price contracts from participating institutions. The content of the survey was vetted by patient advocates with experience in survey design and readability by five patients undergoing breast MRI who were not included in the study and who met inclusion criteria. A professional medical illustrator created infographic information to facilitate patient understanding.

The survey software considered the active ratings of the respondents to generate a personalized choice set that maximized analyzability of their responses. The experiment had a near-orthogonal design with level balance and minimal attribute level overlap. Details of the administered surveys are provided in Supplementary Table 1.

The survey was administered by trained interviewers. Potential participants were recruited by reviewing the daily breast MRI schedule at each participating institution and consenting patients in real-time the day of their examination. Demographic data (patient age, patient ethnicity, indication for MRI) were extracted from the electronic medical record for all screened patients at each site to (1) reduce the question burden from each patient, and (2) to characterize the non-respondent population.

Sample size calculation

An a priori power calculation was performed to estimate the needed sample size. Based on the largest observed standard deviation available from preliminary data, to achieve a ± utility confidence interval length of 10 required 170 patients, and to achieve a ± utility confidence interval length of 5 required 670 patients. The study was terminated after 236 patients had been accrued due to the emerging novel coronavirus disease 2019 (COVID-19) pandemic [20].

Statistical design

Hierarchical Bayesian modeling and a Monte Carlo Markov chain algorithm were used to estimate part-worth utilities (and their 95% confidence intervals) for each GBCM attribute [21–23]. A total of 50,000 posterior simulation iterations were used. Part-worth utilities were an interval measure of patient preference for levels within an attribute—somewhat analogous to a beta coefficient from a logistic regression. To aid interpretation, part-worth utilities were zero-centered so that positive values indicated increased likelihood of selection and negative values indicated decreased likelihood of selection.

Attribute importance is the estimated average relative importance participants placed on a given attribute when making GBCM selection decisions. For each participant, attribute importance was calculated as the range of their part-worth utilities for that attribute, divided by the sum of the ranges for all attributes, multiplied by 100 (i.e., \( \frac{\text{Specific attribute utility range}}{\sum \text{All attribute utility ranges}} \times 100 \)). The average attribute importance was reported as a percentage and a 95% confidence interval. Attribute importances summed to 100%.

Demographic data were summarized with descriptive statistics. Patient-specific attribute importances were modeled using linear regression. The covariates used for analysis included age, education, health insurance, employment, household income, and previous allergic-like reaction to GBCM. The mean attribute importance difference was calculated between each covariate subgroup.

Statistical analysis was performed using SAS software (v9.4). For primary endpoints, \( p < 0.05 \) is considered significant. For secondary endpoints (i.e., when assessing differences in attribute importance), \( p < 0.01 \) was considered significant to account for multiple comparisons.

Creating a GBCM preference simulator based on patient preference data

We created a simulator that could be used to ascertain how current and future (i.e., hypothetical) GBCM products would perform in the marketplace (relative to each other) if GBCM selection was solely based on the patient preference data we collected in our multi-site study. Utility values for a combination of GBCM properties were combined to build a multiproduct competitive model using the randomized first choice method to estimate share of preference. Patient-specific share of preference for a GBCM was calculated as the antilog of the total product utility (based on patient-specific part-worth utilities). Results for each product were rescaled to sum to 100%. Overall share of preference was calculated as the mean of patient-specific shares of preference. Patient-centered simulations were performed to compare 3 existing GBCM (using published data) with 3 hypothetical GBCM using the patient-level part-worth utilities derived from our study. The specific GBCM property information is included in Table 1. Although these six GBCM (3 existing, 3 hypothetical) were the only GBCM formally analyzed in our simulations, the simulator derived from our data (Supplementary Material) permits the user to input any combination of attribute.
levels based on existing or novel GBCM to determine its hypothetical value (from the patient’s perspective) vs. a user-defined number of competitor GBCM.

**Results**

**Patient characteristics**

The survey response (87% [247 of 284]) and completion (96% [236 of 247]) rates were excellent. A total of 284 patients were approached to participate; 247 agreed to participate and 236 completed the survey. Incomplete surveys (N = 11) were excluded from analysis. A study population flow diagram is provided in Fig. 1. Non-responders (N = 37) had similar demographics to responders (N = 236) (Table 2). Recruitment distribution from the four sites was as follows: site 1 (38% [90 of 236]); site 2 (30% [70 of 236]); site 3 (16% [38 of 236]); site 4 (16% [38 of 236]). Details of our study population are provided in Table 2.

A majority (85% [201 of 236]) of participants were white with a mean age of 50 ± 11.9 years. Most had a household income greater than $75,000 (77% [158 of 204] among those reporting income), were college educated (70% [164 of 236]), had full-time employment (64% [150 of 236]), and had an employer-based insurance plan (75% [176 of 236]). Only 2% (5 of 236) reported a previous allergic-like reaction to GBCM.

**Importance of GBCM attributes**

The values respondents ascribed to each GBCM attribute, expressed as part-worth utilities, are included in Fig. 2, with pairwise comparisons between levels provided in Supplementary Table 2. Participants preferred (p < 0.001) greater cancer detection sensitivity, lower cost, less intracranial gadolinium retention, and lower mild and severe allergic-like reaction rates (Fig. 2, Table 3). Patients considered cancer detection sensitivity to be the most important GBCM attribute (Fig. 2, Table 3). GBCM attributes are listed as follows in descending order of importance (% Table 3): (1) cancer detection sensitivity (44.3%, 95%CI 42.0–46.7%), (2) mild allergic-like reaction rate (19.5%, 95%CI 17.9–21.1%), (3) severe allergic-like reaction rate (17.0%, 95%CI 15.8–18.1%), (4) intracranial gadolinium retention (11.6%, 95%CI 10.5–12.7%), (5) out-of-pocket cost (7.5%, 95%CI 6.8–8.3%). Intracranial gadolinium retention was considered by patients to be less important than cancer detection sensitivity and allergic-like reaction rates (mild and severe), but more important than out-of-pocket cost.

Attribute importance varied by several factors including household income and educational attainment (Table 3, Supplementary Table 3). Compared to patients with an annual income > $150,000, patients with an annual income < $25,000 placed less value on cancer detection sensitivity (importance...
| Characteristic                                         | Responders (n = 236) | Non-responders (n = 37) |
|--------------------------------------------------------|----------------------|-------------------------|
| Age (years)                                            |                      |                         |
| Mean (SD)                                              | 50 (11.9)            | 53 (12.5)               |
| Median (1st quartile to 3rd quartile)                  | 51 (41 to 59)        | 52 (44 to 61)           |
| Range                                                  | 26 to 77             | 27 to 75                |
| Gender, n (%)                                          |                      |                         |
| Female                                                 | 236 (100)            | 37 (100)                |
| Race, n (%)                                            |                      |                         |
| White                                                  | 201 (85)             | 37 (100)                |
| Hispanic                                               | 9 (4)                | 0 (0)                   |
| Black                                                  | 15 (6)               | 0 (0)                   |
| Asian                                                  | 10 (4)               | 0 (0)                   |
| Other                                                  | 1 (0)                | 0 (0)                   |
| Breast cancer risk, n (%)                              |                      |                         |
| High-risk mutation (BRCA1, BRCA2, other)               | 64 (27)              | 6 (16)                  |
| Untested, first-degree relative with high-risk mutation| 12 (5)               | 0 (0)                   |
| Chest radiation between 10 and 30 years of age         | 9 (4)                | 2 (5)                   |
| > 20% lifetime risk of breast cancer                   | 179 (76)             | 22 (60)                 |
| One or more intermediate risk factors                  | 88 (37)              | 20 (54)                 |
| Education, n (%)                                       |                      |                         |
| Less than high school                                   | 2 (1)                |                         |
| High school graduate                                    | 26 (11)              |                         |
| Trade/technical/vocational                             | 17 (7)               |                         |
| Associates degree                                       | 26 (11)              |                         |
| Bachelor degree                                         | 74 (31)              |                         |
| Master or Doctorate degree                             | 90 (38)              |                         |
| Prefer not to answer                                    | 1 (0)                |                         |
| Health insurance, n (%)                                |                      |                         |
| Self-insured                                           | 11 (5)               |                         |
| Employer-based plan                                     | 176 (75)             |                         |
| Medicaid                                               | 12 (5)               |                         |
| Medicare                                               | 22 (9)               |                         |
| Other                                                   | 15 (6)               |                         |
| Employment status, n (%)                               |                      |                         |
| Full-time employment                                    | 150 (64)             |                         |
| Part-time employment                                    | 28 (12)              |                         |
| Disabled                                               | 6 (3)                |                         |
| Unemployed                                             | 14 (6)               |                         |
| Retired                                                | 38 (16)              |                         |
| Household income, n (%)                                |                      |                         |
| Less than $25,000                                       | 12 (5)               |                         |
| $25,000–$49,999                                        | 18 (8)               |                         |
| $50,000–$74,999                                        | 16 (7)               |                         |
| $75,000–$99,999                                        | 42 (18)              |                         |
| $100,000–$149,999                                      | 47 (20)              |                         |
| More than $150,000                                     | 69 (29)              |                         |
| Prefer not to answer                                    | 32 (14)              |                         |
| Previous allergic-like reaction to GBCM, n (%)          |                      |                         |
| Yes                                                    | 5 (2)                |                         |
| No                                                     | 231 (98)             |                         |
33.1% vs. 48.8%, \( p < 0.01 \), greater value on out-of-pocket cost (importance 14.9% vs. 5.7%, \( p < 0.01 \)), and greater value on intracranial gadolinium retention (15.7% vs. 10.1%, \( p < 0.01 \)) (Table 2). College-educated patients placed slightly less
### Table 3  Average attribute importance and univariable linear regression results testing differences in mean attribute importance by participant characteristics

| Importance | Sensitivity | Out-of-pocket expense | Gadolinium retention | Severe reaction rate | Mild reaction rate |
|------------|-------------|-----------------------|----------------------|---------------------|--------------------|
| Mean (%) [95% CI] | 44.3 [42.0, 46.7] | 7.5 [6.8, 8.3] | 11.6 [10.5, 12.7] | 17.0 [15.8, 18.1] | 19.5 [17.9, 21.1] |
| Income | | | | | |
| < $25k | 33.1 [23.0, 43.1] | 14.9 [7.1, 22.6] | 15.7 [10.6, 20.8] | 15.6 [11.8, 19.4] | 20.7 [14.4, 27.0] |
| > $150k | 48.8 [45.1, 52.5] | 5.7 [4.9, 6.5] | 10.1 [8.2, 11.9] | 17.7 [15.5, 19.8] | 17.8 [15.2, 20.4] |
| Comparisons: mean importance differences [99% CI] | | | | | |
| Age (/10 years) | −0.9 [−3.5, 1.7] | −0.2 [−1.1, 0.6] | 0.0 [−1.2, 1.2] | 0.9 [−0.4, 2.2] | 0.1 [−1.6, 1.9] |
| College vs. no college | 6.5 [−0.2, 13.2] | −2.8 [−4.9, −0.7] | −0.9 [−4.0, 2.3] | 1.4 [−1.9, 4.7] | −4.2 [−8.8, 0.3] |
| Employer-based insurance vs. others | 1.2 [−5.9, 8.3] | −1.1 [−3.4, 1.2] | −0.2 [−3.5, 3.1] | 0.5 [−2.9, 4.0] | −0.4 [−5.2, 4.4] |
| Full-time work vs. other | −0.4 [−6.9, 6.0] | −1.6 [−3.7, 0.4] | 0.1 [−2.9, 3.1] | 0.7 [−2.4, 3.9] | 1.2 [−3.1, 5.6] |
| Household income | | | | | |
| < $50k vs. ≥ $50k | −9.1 [−18.3, 0.2] | 5.2 [2.3, 8.1] | 5.1 [0.8, 9.3] | −0.2 [−4.8, 4.4] | −1.1 [−74.5, 3] |
| < $75k vs. ≥ $75k | −7.2 [−15.0, 0.7] | 4.7 [2.2, 7.1] | 3.5 [−0.1, 7.2] | −1.0 [−4.9, 2.9] | 0.0 [−5.5, 5.4] |
| < $100k vs. ≥ $100k | −9.4 [−15.9, −2.9] | 3.5 [1.5, 5.6] | 3.0 [−0.1, 6.0] | −0.7 [−4.0, 2.6] | 3.7 [−0.9, 8.2] |
| < $25k vs. ≥ $150k | −15.7 [−30.2, −1.3] | 9.2 [4.7, 13.7] | 5.7 [−1.2, 12.5] | −2.0 [−9.4, 5.3] | 2.9 [−7.1, 12.9] |
| Prior allergic reaction vs. no | −15.3 [−36.6, 6.0] | −1.8 [−8.7, 5.1] | 5.4 [−4.6, 15.3] | 5.3 [−5.2, 15.7] | 6.5 [−8.1, 21.1] |

* p < 0.01. The bold with * emphasizes the values with statistical significance.

Attribute “importance” is the estimated average relative importance participants placed on that attribute when making product selection decisions. For each participant, attribute importance (%) is calculated as the range of their part-worth utilities for that attribute, divided by the sum of the ranges for all attributes multiplied by 100 (i.e., \( \frac{\text{Specific attribute utility range}}{\sum \text{All attribute utility ranges}} \times 100 \)). Reported values in the first row above are the average importance across all 236 participants.
importance on out-of-pocket cost (−2.8%, 99%CI −4.9 to −0.7) (Table 3). However, the rank-ordering of attribute importance between these income and educational strata was nearly the same, and cancer detection sensitivity always had the highest importance. Age, insurance status, employment status, and level of breast cancer risk did not have a significant effect on GBCM attribute importance (Table 3). Race and ethnicity subgroups were insufficiently powered for subgroup analysis.

**Preference share simulator model**

Multi-product competitive simulations were performed to determine which GBCM a population of patients would prefer if they knew the details and were empowered to choose which GBCM they were administered (Table 4). In all simulations, existing product C (macrocyclic, high sensitivity 94%, low intracranial gadolinium retention 0.2 per 100 million molecules, high mild reaction rate 150/100,000, low severe reaction rate 5.7/100,000, intermediate out-of-pocket cost $72) was the most preferred (preference share 57.4–61.7% competing vs. 2–5 other GBCM) (Table 4). This was driven by superior sensitivity for cancer detection, low gadolinium retention, and low severe reaction rate (Table 3).

Hypothetical macrocyclic GBCM (products E and F) with low cancer detection sensitivity (78–83%), low intracranial gadolinium retention (0.1–0.2 per million molecules), and intermediate to high allergic-like reaction rates (mild, 72–130/100,000; severe, 12–18/100,000) were less preferred than two existing linear GBCM (products A and D) with similar cancer detection sensitivity (83%), intermediate to high gadolinium retention (4.5–20 per million molecules), and low allergic-like reaction rates (mild, 12–39/100,000; severe, 1.6–2.1/100,000) (Table 4). Even though the two hypothetical macrocyclic agents had lower intracranial gadolinium retention, the higher patient importance for low mild and severe reaction rates made the linear agents A and D (preference shares: 8.0% and 12.0%) more preferred than macrocyclic agents E and F (preference shares: 1.6% and 0.9%) (Tables 3 and 4).

### Table 4  Simulation results of share of preference

| Scenario    | Sensitivity (%) | Out-of-pocket expense ($) | Gadolinium retention (per 100M molecules) | Severe reaction rate (/100k) | Mild reaction rate (/100k) | Share of preference (%) |
|-------------|-----------------|---------------------------|------------------------------------------|----------------------------|---------------------------|--------------------------|
| Scenario 1  |                 |                           |                                          |                            |                           |                          |
| Existing product A | 83              | 83                        | 4.5                                      | 2.1                       | 39                       | 16.5                     |
| Existing product B | 94              | 100                       | 4                                        | 12                        | 130                      | 21.8                     |
| Existing product C | 94              | 72                        | 0.2                                      | 5.7                       | 150                      | 61.7                     |
| Scenario 2  |                 |                           |                                          |                            |                           |                          |
| Test product D | 83              | 25                        | 20                                       | 1.6                       | 12                       | 13.0                     |
| Existing product A | 83              | 83                        | 4.5                                      | 2.1                       | 39                       | 8.8                      |
| Existing product B | 94              | 100                       | 4                                        | 12                        | 130                      | 20.3                     |
| Existing product C | 94              | 72                        | 0.2                                      | 5.7                       | 150                      | 57.8                     |
| Scenario 3  |                 |                           |                                          |                            |                           |                          |
| Test product E | 78              | 100                       | 0.2                                      | 12                        | 72                       | 2.9                      |
| Existing product A | 83              | 83                        | 4.5                                      | 2.1                       | 39                       | 14.4                     |
| Existing product B | 94              | 100                       | 4                                        | 12                        | 130                      | 21.5                     |
| Existing product C | 94              | 72                        | 0.2                                      | 5.7                       | 150                      | 61.3                     |
| Scenario 4  |                 |                           |                                          |                            |                           |                          |
| Test product F | 83              | 75                        | 0.1                                      | 18                        | 130                      | 1.6                      |
| Existing product A | 83              | 83                        | 4.5                                      | 2.1                       | 39                       | 15.7                     |
| Existing product B | 94              | 100                       | 4                                        | 12                        | 130                      | 21.5                     |
| Existing product C | 94              | 72                        | 0.2                                      | 5.7                       | 150                      | 61.2                     |
| Scenario 5  |                 |                           |                                          |                            |                           |                          |
| Existing product A | 83              | 83                        | 4.5                                      | 2.1                       | 39                       | 8.0                      |
| Existing product B | 94              | 100                       | 4                                        | 12                        | 130                      | 20.1                     |
| Existing product C | 94              | 72                        | 0.2                                      | 5.7                       | 150                      | 57.4                     |
| Test product D | 83              | 25                        | 20                                       | 1.6                       | 12                       | 12.0                     |
| Test product E | 78              | 100                       | 0.2                                      | 12                        | 72                       | 1.6                      |
| Test product F | 83              | 75                        | 0.1                                      | 18                        | 130                      | 0.9                      |
Discussion

Patients at intermediate or high risk for breast cancer undergoing screening MRI screening strongly prioritize cancer detection (attribute importance 44.3%) over GBCM-related risks (attribute importance 11.6–19.5%). This is predictable because patients undergo a test when they perceive the benefits outweigh the risks. It also implies that clinically meaningful differences in GBCM relaxation are likely to be valued by patients. Among GBCM-related risks, patients place greater importance on allergic-like reactions (17.0–19.5%) than gadolinium retention (11.6%), and greater importance on gadolinium retention (11.6%) than out-of-pocket cost (7.5%). These relationships are maintained regardless of patient demographics and background, but the degree of importance patients place on these attributes varies by household income and presence of a college education. We believe these data can be used to inform the selection or innovation of contrast media for patients undergoing repeated lifetime contrast-enhanced MRI—a population potentially at greatest risk of GBCM-related side effects.

GBCM selection from the patient’s perspective is more nuanced than the recent focused attention on gadolinium retention [8]. This point is relevant because newly described potential risks like gadolinium retention sometimes can receive outsized importance in clinical decision-making. In our population, gadolinium retention and cost were less important to patients than allergic-like reaction risks and cancer detection sensitivity. The slightly greater importance patients placed on mild vs. severe reactions likely relates to the ranges of tested prevalence (mild, 10–1000/100,000; severe, 1–19/100,000). The rarity of severe reactions likely counterbalanced their severity. This also illustrates that, from the patient’s perspective, “nuisance” mild reactions have relevance and that relevance is prioritized over the uncertain clinical importance of gadolinium retention. Reaction rates probably should be considered at least as important as (if not more important than) gadolinium retention during GBCM selection.

Despite recruiting from 4 institutions, the demographics of our patient population (white 85%, income > $75,000 77%, college educated 81%, full-time employment 64%, employer-based healthcare 75%) were skewed relative to the US general population [24]. Rather than study-related selection bias, this likely reflects disproportionate access to breast MRI screening in the USA [9–13]. Haas et al (2016) analyzed 316,172 women aged 35–69 years from 5 Breast Cancer Surveillance Consortium registries and found that non-Hispanic white women with < 20% lifetime risk of breast cancer were 62% more likely than non-white women to receive an MRI, and that college-educated women in that cohort were 132% more likely to receive an MRI than those with a high school education or less [9]. In women at high risk (≥ 20% lifetime risk of breast cancer), there was no significant difference in MRI access by race or ethnicity, but high-risk women with no more than a high school education were significantly less likely to receive an MRI than those with a college education (relative risk 0.40) [9].

In our study, household income affected how patients weighted GBCM attributes. In particular, patients with less household income placed greater importance on out-of-pocket cost (+3.5 to +9.2%) and less importance on detection sensitivity (−7.2 to −15.7%). These data reflect how financial pressure affects healthcare decision-making and viewed broadly can contribute to worse clinical outcomes [25–28]. In our study, patients with less income were exchanging diagnostic accuracy for less immediate out-of-pocket cost. Not only were impoverished patients making choices that hypothetically could impair their health, they were less likely to access MRI screening in general. Poverty contributes to poor breast cancer outcomes due to lack of primary care, inadequate health insurance, and poor healthcare access [28].

Finding ways to address the barriers of poverty and other social determinants of health [27] is necessary to attain equity in the US healthcare.

There were several limitations of our study. There was not a pre-existing conjoint instrument for external validation. To address this, we had our instrument reviewed and approved by patient advocates with experience in survey design, used infographics and explanatory text to improve comprehension, and performed precognitive testing for content and readability by five patients prior to dissemination. We intentionally performed our analysis from the patient’s point of view even though patients are not generally involved in choosing a GBCM. This was done to inform radiologists and GBCM vendors which GBCM attributes patients consider most important. We used a breast MRI screening population because this population is exposed to repeated lifetime doses of GBCM, has a vested interest in cancer detection, and is potentially at greatest risk (if any) from long-term gadolinium retention. Our results may be different in other populations (e.g., those receiving a single GBCM dose). Risk of bias in survey administration was minimized by use of professional conjoint software that automates a near-orthogonal design with level balance and minimal attribute level overlap. Sampling bias was minimized by recruiting from 4 institutions and having an excellent response rate (87%).

In conclusion, patients at intermediate or high risk for breast cancer undergoing MRI screening prioritize cancer detection sensitivity over GBCM-related risks, and prioritize reaction risks over gadolinium retention. Although these relationships were consistent across various demographic and socioeconomic strata, patients with less household income were more willing to exchange GBCM diagnostic accuracy for affordability. These data, and the simulator, should be useful.
when selecting or innovating contrast media for patients undergoing annual MR screening.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00330-021-07982-y.

Funding This study was supported by the National Center for Advancing Translational Sciences (NCATS Grant Number: UL1TR002240) for the Michigan Institute for Clinical and Health Research.

Declarations

Guarantor The scientific guarantor of this publication is Sean Woolen MD MSc.

Conflict of interest The authors of this manuscript declare relationships with the following companies:
Jonathan Troost: Unrelated stocks in Procter & Gamble and General Electric
Jennifer McDonald: Investigator- and sponsor-initiated research grants (paid to institution) from GE Healthcare independent of the current study. Serves as a scientific advisor and consultant (paid to institution) to GE Healthcare independent of the current study
Robert McDonald: Investigator- and sponsor-initiated research grants (paid to institution) from GE Healthcare independent of the current study. Serves as a scientific advisor and consultant (paid to institution) to GE Healthcare independent of the current study. Serves as an expert witness for GE Healthcare regarding contrast material safety
Matthew Davenport: Unrelated royalties from Wolters Kluwer
All other authors: No disclosures

Statistics and biometry The authors Jonathan P Troost PhD and Shokoufeh Khalatbari MS have significant statistical expertise.

Informed consent Written informed consent was obtained from all subjects (patients) in this study.

Ethical approval Institutional Review Board approval was obtained at all participating institutions.

Methodology
• prospective,
• observational,
• multicenter study at 4 institutions.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270(3):834–841
2. McDonald RJ, McDonald JS, Kallmes DF et al (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275(3):772–782
3. Murata N, Murata K, Gonzalez-Cuyar LF, Maravilla KR (2016) Gadolinium tissue deposition in brain and bone. Magn Reson Imaging 34(10):1359–1365
4. Gibby WA, Gibby KA, Gibby WA (2004) Comparison of Gd DTPA-BMA (Omniscan) versus Gd Hp-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 39(3):138–142
5. Sardanelli F, Cozzi A, Tribolli RM, Schiaffino S (2020) Gadolinium retention and breast mri screening: more harm than good? AJR Am J Roentgenol 214(2):324–327
6. McDonald RJ, Levine D, Weinreb J et al (2018) Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates. Radiology 298(2):517–534
7. Mithal LB, Patel PS, Mithal D, Palac HL, Rozenfeld MN (2017) Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. Pediatr Radiol 47(6):657–664
8. Davenport MS (2018) Choosing the safest gadolinium-based contrast medium for MR imaging: not so simple after all. Radiology 286(2):483–485
9. Haas JS, Hill DA, Wellman RD et al (2016) Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer 122(4):611–617
10. Werkli KJ, DeMartini WB, Ichikawa L et al (2014) Patterns of breast magnetic resonance imaging use in community practice. JAMA Intern Med 174(1):125–132
11. Ram S, Sarma N, López JE, Liu Y, Li CS, Aminololama-Shakeri S (2018) Impact of the California breast density law on screening breast MR utilization, provider ordering practices, and patient demographics. J Am Coll Radiol 15(4):594–600
12. Miles R, Wan F, Onega TL et al (2018) Underutilization of supplemental magnetic resonance imaging screening among patients at high breast cancer risk. J Womens Health (Larchmt) 27(6):748–754
13. Onega T, Lee CL, Benkeser D et al (2016) Travel burden to breast MRI and utilization: are risk and sociodemographics related? J Am Coll Radiol 13(6):611–619
14. Saslow D, Boetes C, Burke W et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57(2):75–89
15. Sawtooth Software (2014) Discover-CBC: how and why it differs from SSI Web’s CBC Software. Available via http://www.sawtoothsoftware.com/download/SaaS_CBC_White_Paper.pdf. Accessed 1 Jul 2020
16. Martinecch L, Faivre-Pierret M, Zechmann CM et al (2011) Multicenter, double-blind, randomized, intranidividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT Trial). Radiology 258(2):396–408
17. Pediocomi F, Kubik-Huch R, Chilla B, Schwenke C, Kinkel K (2013) Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for pre-operative breast MRI. Eur Radiol 23(1):84–92
18. Jost G, Frenzel T, Boyken J, Lohrke J, Nischwitz V, Pietsch H (2019) Long-term excretion of gadolinium-based contrast agents: linear versus macrocyclic agents in an experimental rat model. Radiology 290(2):340–348

19. Behzadi AH, Zhao Y, Farooq Z, Prince MR (2018) Immediate allergic reactions to gadolinium-based contrast agents: a systematic review and meta-analysis. Radiology 286(2):471–482

20. Fleming TR, Labriola D, Wittes J (2020) Conducting clinical research during the COVID-19 pandemic: protecting scientific integrity. JAMA 324(1):33–34

21. Hauber AB, González JM, Groothuis-Oudshoorn CG et al (2016) Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health 19(4):300–315

22. Kuhfeld W. SAS Technical Papers (2010) Marketing research methods in SAS, Technical report, SAS Institute Inc. Accessed via http://support.sas.com/resources/papers/tnote/tnote_marketresearch.html. Accessed 8 Sept 2020

23. Lahiri K, Gao J (2002) Bayesian analysis of nested logit model by Markov chain Monte Carlo. SSRN 1–72

24. United States Census Bureau (2019) Quick facts. Available via https://www.census.gov/quickfacts/fact/table/US/PST045219. Accessed 28 Aug 2020

25. Gornick ME, Eggers PW, Reilly TW et al (1996) Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 335(11):791–799

26. Mills A (2014) Health care systems in low- and middle-income countries. N Engl J Med 370(6):552–557

27. NEJM Catalyst (2017) Social determinants of health (SDOH). Accessed via https://catalyst.nejm.org/doi/full/10.1056/CAT.17.0312. Accessed 28 Aug 2020

28. Gerend MA, Pai M (2008) Social determinants of Black-White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev 17(11):2913–2923

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.